Navigation Links
Cancer drug holds promise as first treatment for common, inherited dementia
Date:5/31/2011

ce to clinical trials, the team established a method to quickly screen 1,200 drugs that already had Food and Drug Administration approval. SAHA emerged as the most active of the chemicals they screened, said lead author and graduate student Basar Cenik, who works in the laboratories of both Dr. Herz and co-senior author Dr. Gang Yu, associate professor of neuroscience.

SAHA is in a class of drugs called histone deacetylase inhibitors, and is approved for use in a cancer called cutaneous T-cell lymphoma.

"We found a drug that can overcome the chemical deficiency associated with the condition, and we showed that it worked in cells taken from humans with FTD," Dr. Yu said.

It is not yet known if the drug will efficiently cross the blood-brain barrier, a biologically protective system that keeps many chemicals from reaching the brain, Dr. Yu said. The next research step, he said, will be to screen larger chemical libraries in an effort to find other promising GRN-stimulating drugs for human trials.

Drs. Herz and Yu are both investigators for the Consortium for Frontotemporal Dementia Research and are working toward human trials with that national network, which is based at the University of California at San Francisco.


'/>"/>

Contact: Deborah Wormser
deborah.wormser@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Breast cancer treatment resistance linked to signaling pathway
2. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
3. The dietary supplement genistein can undermine breast cancer treatment
4. Saliva proteins could help detection of oral cancer
5. Vitamin C supplements may reduce benefit from wide range of anti-cancer drugs
6. Breakthrough optical technology to assess colon cancer risk, accuracy
7. Breast cancer cells recycle to escape death by hormonal therapy
8. Nanodiamond drug device could transform cancer treatment
9. Second lumpectomy for breast cancer reduces survival rates
10. Study looks at psychological impact of gene test for breast cancer
11. SNM releases new fact sheet on breast cancer and molecular imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... June 30, 2015 To bolster its efforts and ... Corp. announced today the addition of two new team members. ... board advisor and David Raviv will act as ... HYPR Corp.,s commitment to providing the most secure solutions for ... co-founded Layer 7 Technologies, a provider of security and ...
(Date:6/25/2015)... June 25, 2015 According ... Type (Swipe & Area), Technology, Material (Optical Prism, ... Commercial Security & Others) & Geography - Global ... the said market is expected to reach $14,500.07 ... Browse 76 market Tables and ...
(Date:6/24/2015)... YORK , June 24, 2015 This ... market, over the next six years. It contains an ... the industry, along with their impact from the short, ... It also discusses the industry, market, and technology trends ... that the need of concerned authorities to efficiently manage ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... computer-imaging technology to produce stunning three-dimensional pictures of ... piece of fossilized amber resin. University of ... the intricate images using X-ray computed tomography to ... seen under the microscope in the old and ...
... available in German . , "Seeing something ... Joachim Fischer and Tolga Ergin. For about one year, both ... at KIT,s Center for Functional Nanostructures (CFN) have worked on ... an extent that it is also effective in the visible ...
... in your spring garden may still be struggling to reach the ... within each seed. Once those resources are depleted, the plant cell ... Researchers at the Salk Institute for Biological Studies recently showed a ... published in the May 24, 2011, issue of the journal ...
Cached Biology News:Imaging technology reveals intricate details of 49-million-year-old spider 2Karlsruhe invisibility cloak: Disappearing visibly 2It's not easy being green 2It's not easy being green 3
(Date:7/28/2015)... , July 28, 2015  Moerae Matrix Inc. ... 1 clinical trial with MMI-0100, a first-in-class inhibitor ... developed for pulmonary disorders characterized by inflammation and ... United Kingdom , is a double-blind, two-way ... the safety and tolerability of MMI-0100 when given ...
(Date:7/28/2015)... ZIONA, Israel , July ... (TASE:CLPT; OTC:CQPTY), a regenerative medicine company utilizing its ... today announced that Shomrat Shurtz has been appointed ... 2015.      (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ... 25 years of experience in marketing, regulatory and ...
(Date:7/27/2015)... Dallas, TX (PRWEB) , ... July 27, 2015 ... ... the current state of the Biophotonics industry.The report provides a basic overview of ... analysis is provided for the international markets including development trends, competitive landscape analysis, ...
(Date:7/27/2015)... ... July 27, 2015 , ... ... network Monday. The venture will bring the world’s most efficient gas dissolution technology ... equipment and technologies to both the industrial and municipal markets. With offices located ...
Breaking Biology Technology:Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2CollPlant Names Shomrat Shurtz Senior Director of Business Development 22015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3BlueInGreen Brings Water Treatment Technology to Florida 2
... Aug. 7 Novavax, Inc. (Nasdaq: NVAX ) today reported a ... of 2009 compared to a net loss of $9.4 million, or $0.15 per ... For the six months ended June 30, 2009, Novavax reported a net ... loss of $17.1 million, or $0.28 per share, for the six months ended ...
... , , BRISBANE, Calif., Aug. 7 ... Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will ... Boston on August 12, 2009 at 10:30 a.m. EDT. , ... presentation, investors and other interested parties may log on to the ...
... , , SALEM, N.H., Aug. 7 ALPCO Diagnostics ... c tin EL I SA kit ... it is a departure from other methods for determining mouse HMW adiponectin ... Dr. Hiroyuki Ebinuma of the Tsukuba Research Institute in the journal Clinica ...
Cached Biology Technology:Novavax Reports Second Quarter 2009 Financial Results 2Novavax Reports Second Quarter 2009 Financial Results 3Novavax Reports Second Quarter 2009 Financial Results 4Novavax Reports Second Quarter 2009 Financial Results 5Novavax Reports Second Quarter 2009 Financial Results 6Novavax Reports Second Quarter 2009 Financial Results 7Novavax Reports Second Quarter 2009 Financial Results 8Novavax Reports Second Quarter 2009 Financial Results 9ALPCO Introduces a Mouse HMW and Total Adiponectin ELISA 2
COMING SOON: Anti-Mouse CD205 (DEC-205),Clone NLDC-145, mAb...
... clone 41D GenBank Accession Number ... clusterin purified from human serum Formulation: ... and 0.05% sodium azide Quality Assurance: ... HeLa cells or MCF-7 cell lysates. ...
Component in MasterPure™ Purification Kits...
Mouse monoclonal [TU-20] to beta III Tubulin (FITC) ( Abpromise for all tested applications). entrezGeneID: 10381 SwissProtID: Q13509...
Biology Products: